TATVANSETATVA CHIN PHARM CHEM LTDMediumNeutral
Announced Fri, 17 Jul · 15:48 IST

Tatva Chintan: Q1 results, capacity expansion, director re-appointments, higher borrowing limit

Management Changes View source PDF

TATVA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+18.3%1-day move
₹1430.00
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+18.3+16.2+19.6+20.2+27.1
Up moveDown movePending
AI summary

Board approved Q1 FY27 consolidated revenue of Rs 1,670.55 million, profit after tax Rs 159.81 million, EPS Rs 6.83. Re-appointed MD Chintan Shah and whole-time directors Ajaykumar Patel and Shekhar Somani for 3 more years from Feb 2027. Approved new greenfield unit Dahej-III with 344 KL reactor capacity, about Rs 200 Crores investment over 21 months. Borrowing limit raised from Rs 300 Crores to Rs 1,000 Crores.

Likely market impact

Strong Q1 results and growth capex are positive. Three-times jump in borrowing limit and Rs 200 Cr capex may pressure near-term returns. Director continuity reassures.